ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).

Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of switching from treatment with sMRAs to finerenone in patients with CKD and T2D across multiple centres in Madrid.

Findings showed that potassium levels significantly decreased in patients who switched from sMRAs to finerenone. Furthermore, albuminuria and eGFR levels in patents who switched treatments decrease at an equal level to patients on sMRAs.

Interview Questions:
1. What is the reasoning behind the study?
2. What was the study design, patient population and the key findings?
3. How should these findings impact clinical practice?
4. What further research is needed in this area?

Recorded on-site at ERA in Vienna, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: David Ben-Harosh, Tom Green

Support: This is an independent interview produced by Radcliffe CVRM.